Brief: Mesoblast Says FDA Approves New Potency Assay For Commercial Ryoncil
24/09/2026 02:32
BRIEF-Mesoblast Says FDA Approves New Potency Assay For Commercial Ryoncil Sept 24 (Reuters) - Mesoblast Limited MSB.AX:
FDA APPROVES NEW POTENCY ASSAY FOR COMMERCIAL RYONCIL
RECEIVES FDA APPROVAL FOR NEW POTENCY ASSAY FOR COMMERCIAL RYONCIL PRODUCT
Further company coverage: MSB.AX
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Mesoblast
See all newsBrief: Mesoblast William Burns To Retire From Board At 2026 AGM
Brief: Mesoblast Says Q1 Net Revenues Up 44%
Australia's Mesoblast hits one-month high on upbeat quarterly update
Australia's Mesoblast drops as Bell Potter cuts target price after key drug misses sales view
Brief: Mesoblast Says FDA Approves New Potency Assay For Commercial Ryoncil